

CITATION REPORT

List of articles citing

Schizophrenia, "just the facts" what we know in 2008.
2. Epidemiology and etiology

DOI: 10.1016/j.schres.2008.04.011
Schizophrenia Research, 2008, 102, 1-18.

Source: <https://exaly.com/paper-pdf/44115377/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
572	Epidemiological survey of mental disorders in the people aged 18 and older in Hebei Province. <i>Asian Journal of Psychiatry</i> , 2008 , 1, 51-5	6.7	21
571	Nosological status and definition of schizophrenia: Some considerations for DSM-V and ICD-11. <i>Asian Journal of Psychiatry</i> , 2008 , 1, 22-7	6.7	36
570	Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. <i>Schizophrenia Research</i> , 2008 , 106, 89-107	3.6	252
569	Which environments for G x E? A user perspective on the roles of trauma and structural discrimination in the onset and course of schizophrenia. 2008 , 34, 1106-10		18
568	Can epigenetics help in the discovery of therapeutics for psychiatric disorders, especially schizophrenia?. 2009 , 4, 621-7		4
567	The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia. 2009 , 87, 256-65		69
566	Deep brain stimulation for schizophrenia. 2009 , 87, 266		9
565	Schizophrenia: the "BLOC" may be in the endosomes. 2009 , 2, pe66		34
564	Cardiometabolic effects of physical activity interventions for people with schizophrenia. 2009 , 14, 388-398		41
563	Prospective study of peer victimization in childhood and psychotic symptoms in a nonclinical population at age 12 years. 2009 , 66, 527-36		260
562	Redox dysregulation, neurodevelopment, and schizophrenia. 2009 , 19, 220-30		297
561	Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. 2009 , 30, 1139-52		44
560	Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. 2009 , 115, 3555-62		122
559	Behavioral perturbations after prenatal neurogenesis disturbance in female rat. 2009 , 15, 311-20		37
558	Recent advances in treating cognitive impairment in schizophrenia. 2009 , 202, 259-73		38
557	The abilities of improved schizophrenia patients to work and live independently in the community: a 10-year long-term outcome study from Mumbai, India. 2009 , 8, 24		10
556	Copy number variation showers in schizophrenia: an emerging hypothesis. 2009 , 14, 356-8		12

555	Common variants on chromosome 6p22.1 are associated with schizophrenia. 2009 , 460, 753-7		919
554	Immune involvement in schizophrenia and autism: etiology, pathology and animal models. 2009 , 204, 313-21		567
553	Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. 2009 , 204, 258-73		47
552	Psychedelics and schizophrenia. 2009 , 32, 225-32		143
551	One-carbon metabolism and schizophrenia: current challenges and future directions. 2009 , 15, 562-70		61
550	Endophenotypes in schizophrenia: a selective review. <i>Schizophrenia Research</i> , 2009 , 109, 24-37	3.6	159
549	Schizophrenia, "just the facts" 4. Clinical features and conceptualization. <i>Schizophrenia Research</i> , 2009 , 110, 1-23	3.6	636
548	Exomic sequencing of the ionotropic glutamate receptor N-methyl-D-aspartate 3A gene (GRIN3A) reveals no association with schizophrenia. <i>Schizophrenia Research</i> , 2009 , 114, 25-32	3.6	12
547	Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. <i>Schizophrenia Research</i> , 2009 , 115, 30-40	3.6	44
546	Common variants in polygenic schizophrenia. 2009 , 10, 236		30
545	Second-generation antipsychotic long-acting injections: systematic review. 2009 , 52, S29-36		45
544	Towards a neurodevelopmental model of clinical case formulation. 2009 , 32, 199-211		2
543	Psychiatric and general medical conditions comorbid with schizophrenia in the National Hospital Discharge Survey. 2009 , 60, 1059-67		61
542	Ziprasidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009 , CD006627.2		33
541	Aripiprazole versus other atypical antipsychotics for schizophrenia. 2009 , CD006569		51
540	Quetiapine versus other atypical antipsychotics for schizophrenia. 2010 , CD006625		33
539	Zotepine versus other atypical antipsychotics for schizophrenia. 2010 , CD006628		8
538	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006628	5.2	5

537	Systematic reviews of categorical versus continuum models in psychosis: evidence for discontinuous subpopulations underlying a psychometric continuum. Implications for DSM-V, DSM-VI, and DSM-VII. 2010 , 6, 391-419		200
536	Social and clinical comparison between schizophrenia and bipolar disorder type I with psychosis in Costa Rica. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010 , 45, 675-80	4.5	9
535	Adoption, family relations and psychotic symptoms among Palauan adolescents who are genetically at risk for developing schizophrenia. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2010 , 45, 1105-14	4.5	9
534	The volumetric differences of the fronto-temporal region in young offspring of schizophrenic patients. 2010 , 19, 151-7		23
533	Two four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study. 2010 , 6, 27		21
532	The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: a multi-centre case-control study and meta-analysis. 2010 , 153B, 387-396		43
531	3-Aryl-5-phenoxyethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. 2010 , 20, 3129-33		37
530	Ethnic origin and increased risk for schizophrenia in immigrants to countries of recent and longstanding immigration. 2010 , 121, 325-39		61
529	Schizophrenia in women: implications for pregnancy and postpartum. 2010 , 14, 482-94; quiz 495		2
528	Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice. 2010 , 31, 349-58		66
527	Reduced fertility in patients' families is consistent with the sexual selection model of schizophrenia and schizotypy. <i>PLoS ONE</i> , 2010 , 5, e16040	3.7	10
526	Beyond the first episode: candidate factors for a risk prediction model of schizophrenia. 2010 , 22, 202-23		5
525	Prenatal Factors in Schizophrenia. 2010 , 19, 209-213		14
524	First episode psychosis and employment: a review. 2010 , 22, 148-62		135
523	Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency. 2010 , 19, 861-78		56
522	DSM, ICD, and psychiatric nosology: How do cultural and national differences factor in?. <i>Asian Journal of Psychiatry</i> , 2010 , 3, 1-2	6.7	
521	Evaluation of carotenoid level in schizophrenic patients using non-invasive measurement. <i>Asian Journal of Psychiatry</i> , 2010 , 3, 190-3	6.7	2
520	De novo truncating mutation in Kinesin 17 associated with schizophrenia. 2010 , 68, 649-56		41

519	Antibodies to measles in individuals with recent onset psychosis. <i>Schizophrenia Research</i> , 2010 , 119, 89-94		18
518	Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. <i>Schizophrenia Research</i> , 2010 , 122, 1-23	3.6	255
517	Updated meta-analyses reveal thalamus volume reduction in patients with first-episode and chronic schizophrenia. <i>Schizophrenia Research</i> , 2010 , 123, 1-14	3.6	73
516	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006624	4.2	20
515	Semantic processing of emotional words in depression and schizophrenia. 2010 , 75, 211-5		17
514	Epidemiology-driven neurodevelopmental animal models of schizophrenia. 2010 , 90, 285-326		288
513	Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. 2010 , 92, 370-85		228
512	Cocaine and amphetamine regulated transcript (CART) gene in the comorbidity of schizophrenia with alcohol use disorders and nicotine dependence. 2010 , 34, 834-6		7
511	An exploratory model for G x E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. 2010 , 34, 1259-65		31
510	Uncovering the roles of rare variants in common disease through whole-genome sequencing. 2010 , 11, 415-25		1082
509	Narrowing the boundaries of the genetic architecture of schizophrenia. 2010 , 36, 14-23		86
508	Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor. 2010 , 1, 406-10		20
507	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010 , CD006654	5.2	87
506	Transgenic and Mutant Tools to Model Brain Disorders. 2010 ,		2
505	Genetics in psychiatry: are the promises met?. <i>World Journal of Biological Psychiatry</i> , 2011 , 12, 81-8	3.8	25
504	Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in <i>Drosophila</i> . 2011 , 108, 18831-6		36
503	Converging evidence of blood-based biomarkers for schizophrenia: an update. 2011 , 101, 95-144		40
502	Alexithymia and personality disorder functioning styles in paranoid schizophrenia. 2011 , 44, 371-8		14

501	DISC1 is associated with cortical thickness and neural efficiency. 2011 , 57, 1591-600		44
500	Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. <i>Schizophrenia Research</i> , 2011 , 126, 184-91	3.6	68
499	Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. <i>Schizophrenia Research</i> , 2011 , 127, 3-13	3.6	146
498	Moving on in Schizophrenia Research to the next decade. <i>Schizophrenia Research</i> , 2011 , 127, 14-5	3.6	8
497	Reconceptualizing schizophrenia. <i>Schizophrenia Research</i> , 2011 , 127, 1-2	3.6	6
496	What Kraepelin might say about schizophrenia: just the facts. <i>Schizophrenia Research</i> , 2011 , 128, 1-2	3.6	3
495	The facts of schizophrenia: a personal commentary. <i>Schizophrenia Research</i> , 2011 , 128, 3-4	3.6	12
494	"Just the facts": meandering in schizophrenia's many forests. <i>Schizophrenia Research</i> , 2011 , 128, 5-6	3.6	5
493	Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. <i>Schizophrenia Research</i> , 2011 , 129, 47-51	3.6	23
492	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2011 , CD006625, 2		58
491	Les troubles psychotiques post-traumatiques : un modèle physiopathologique de la schizophrénie. 2011 , 169, 155-159		
490	Anti-inflammatory signaling in schizophrenia. 2011 , 25, 1507-18		52
489	Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. 2011 , 117, 241-9		34
488	Genetic variation in FOXP2 alters grey matter concentrations in schizophrenia patients. 2011 , 493, 131-5		28
487	Minor physical anomalies: potentially informative vestiges of fetal developmental disruptions in schizophrenia. 2011 , 29, 245-50		23
486	Association of calcineurin A gamma subunit (PPP3CC) and early growth response 3 (EGR3) gene polymorphisms with susceptibility to schizophrenia in a Japanese population. 2011 , 185, 16-9		17
485	A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. <i>Schizophrenia Research</i> , 2011 , 133, 133-42	3.6	117
484	Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia. 2011 , 21, 300-5		15

483	Clinical potential of lurasidone in the management of schizophrenia. 2011 , 7, 239-50	26
482	Challenges of analysing gene-environment interactions in mouse models of schizophrenia. 2011 , 11, 1411-20	16
481	Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. 2011 , 5, 1	116
480	Positive association of the human STON2 gene with schizophrenia. 2011 , 22, 288-93	13
479	Childhood exposure to ionizing radiation to the head and risk of schizophrenia. 2011 , 176, 670-7	14
478	The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?. 2011 , 7, 57-63	
477	Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment. 2011 , 20, 317-27	39
476	Genetic contributions to behavioural diversity at the gene-environment interface. 2011 , 12, 809-20	70
475	Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. 2011 , 16, 293-306	128
474	Cross-ethnic differences in severity of symptomatology of individuals with first-episode schizophrenia spectrum disorder. 2011 , 5, 242-8	17
473	Violence among persons diagnosed with schizophrenia: how pharmacists can help. 2011 , 7, 421-9	2
472	Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. 2011 , 132, 96-110	185
471	Neuroprotection of paliperidone on SH-SY5Y cells against Amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. 2011 , 217, 397-410	16
470	A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia. 2011 , 27, 258-68	3
469	Nonaffective acute psychoses: uncertainties on the way to DSM-V and ICD-11. 2011 , 13, 203-10	20
468	Familial liability, obstetric complications and childhood development abnormalities in early onset schizophrenia: a case control study. 2011 , 11, 60	12
467	Following the genes: a framework for animal modeling of psychiatric disorders. 2011 , 9, 76	15
466	Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese. 2011 , 7, 42	29

465	Paternal age at birth of first child and risk of schizophrenia. 2011 , 168, 82-8	103
464	Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?. 2011 , 10, 19-31	45
463	Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. 2011 , 25, 822-35	17
462	lloperidone: Efficacy Review for the Acute Treatment of Schizophrenia in Adults. 2011 , 3, 279-286	
461	Rethinking the genetic architecture of schizophrenia. 2011 , 41, 19-32	47
460	A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. 2011 , 41, 897-910	327
459	Increased risk of schizophrenia following traumatic brain injury: a 5-year follow-up study in Taiwan. 2011 , 41, 1271-7	11
458	Posttranslational Histone Modifications and the Neurobiology of Psychosis. 2011 , 1-21	
457	Epidemiology of Schizophrenia. 2011 , 263-287	7
456	[Does cannabis use lead to schizophrenia?]. 2011 , 100, 1361-7	
455	A population genetic approach to mapping neurological disorder genes using deep resequencing. 2011 , 7, e1001318	72
454	Psychopharmacology of schizophrenia: The Future Looks Bleak. 2012 , 10, 4-12	5
453	Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. 2012 , 2, 345-353	40
452	All-cause mortality and medication risk factors in schizophrenia: a prospective cohort study. 2012 , 32, 31-5	20
451	Converging evidence that sequence variations in the novel candidate gene MAP2K7 (MKK7) are functionally associated with schizophrenia. 2012 , 21, 4910-21	36
450	Psychotherapie der Schizophrenie. 2012 , 6, 345-360	
449	Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1. 2012 , 32, 3697-711	74
448	Traumatic experience, cannabis use, life satisfaction, and schizotypy. 2012 , 4, 126-136	1

447	Pseudo-ADHD in a case of first-episode schizophrenia: diagnostic and treatment challenges. 2012 , 20, 309-17		1
446	Poor school performance in offspring of patients with schizophrenia: what are the mechanisms?. 2012 , 42, 111-23		21
445	Comparison of experiences of stress and coping between young people at risk of psychosis and a non-clinical cohort. 2012 , 40, 69-88		42
444	The cultural adaptability of intermediate measures of functional outcome in schizophrenia. 2012 , 38, 630-41		22
443	Glutamate and psychosis risk. 2012 , 18, 466-78		32
442	The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities. <i>Current Topics in Medicinal Chemistry</i> , 2012 , 12, 2324-38	3	58
441	Current progress in the genetic research of schizophrenia: relevance for drug discovery?. 2012 , 13, 1614-21		1
440	Genetic variation underlying psychosis-inducing effects of cannabis: critical review and future directions. 2012 , 18, 5015-23		35
439	Multilocus association analysis under polygenic models. 2012 , 6, 482-9		2
438	Cognitive behaviour therapy (group) for schizophrenia. <i>The Cochrane Library</i> , 2012 ,	5.2	4
437	Genetic and functional analysis of the gene encoding GAP-43 in schizophrenia. <i>Schizophrenia Research</i> , 2012 , 134, 239-45	3.6	7
436	Genetics of schizophrenia from a clinical perspective. 2012 , 24, 393-404		9
435	Meta-analysis of the association of urbanicity with schizophrenia. 2012 , 38, 1118-23		265
434	Prevalence of antibodies to <i>Toxoplasma gondii</i> in patients with schizophrenia and mood disorders. <i>Schizophrenia Research</i> , 2012 , 142, 244-5	3.6	12
433	Relationship of metacognition, absorption, and depersonalization in patients with auditory hallucinations. 2012 , 51, 100-18		38
432	Type-2 diabetes mellitus in schizophrenia: increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. 2012 , 27, 33-42		52
431	Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. 2012 , 200, 1022-5		32
430	Cognitive disorganisation in schizotypy is associated with deterioration in visual backward masking. 2012 , 200, 652-9		37

429	The core Gestalt of schizophrenia. 2012 , 11, 67-9		84
428	Religious delusions and filicide: a psychodynamic model. 2012 , 15, 529-549		9
427	Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. 2012 , 18, 180-200		206
426	Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. 2012 , 46, 153-60		9
425	Lack of support for association between the copy number variants in the FCGR locus and schizophrenia: a case control study. 2012 , 522, 85-91		1
424	Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. 2012 , 267-95		130
423	Immune system gene dysregulation in autism and schizophrenia. 2012 , 72, 1277-87		78
422	Schizophrenia shows a unique metabolomics signature in plasma. <i>Translational Psychiatry</i> , 2012 , 2, e149 8.6		111
421	The nosology of schizophrenia: toward DSM-5 and ICD-11. 2012 , 35, 557-69		45
420	Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. 2012 , 42, 1865-71		77
419	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. 2012 , 39, 376-81		9
418	Infectious agents associated with schizophrenia: a meta-analysis. <i>Schizophrenia Research</i> , 2012 , 136, 128-36		158
417	Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. <i>Schizophrenia Research</i> , 2012 , 137, 141-6	3.6	35
416	Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. <i>Schizophrenia Research</i> , 2012 , 137, 50-7	3.6	50
415	Multivariate prediction of emerging psychosis in adolescents at high risk for schizophrenia. <i>Schizophrenia Research</i> , 2012 , 141, 189-96	3.6	41
414	Obsessive-compulsive symptoms in schizophrenia: prevalence, clinical features and treatment. A literature review. <i>World Journal of Biological Psychiatry</i> , 2012 , 13, 2-13	3.8	13
413	Schizophrenia and the immune system: pathophysiology, prevention, and treatment. 2012 , 69, 757-66		32
412	Symptoomdimensiescores zijn geassocieerd met progressieve hersenvolumeveranderingen bij schizofrenie. 2012 , 16, 121-129		

411	Current Schizophrenia. 2012 ,		0
410	Predictors of vocational recovery among young people with first-episode psychosis: findings from a randomized controlled trial. 2012 , 35, 421-7		29
409	Le traumatisme crânien comme facteur étiopathogénique de déclenchement d'une maladie schizo-phrénique. Illustrations des difficultés et intérêts théoriques et pratiques d'une telle conception. 2012 , 77, 403-417		2
408	Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. <i>PLoS ONE</i> , 2012 , 7, e31660	3.7	297
407	Assessment of behaviors modeling aspects of schizophrenia in <i>Csmd1</i> mutant mice. <i>PLoS ONE</i> , 2012 , 7, e51235	3.7	22
406	Do genes and environment meet to regulate cerebrospinal fluid dynamics? Relevance for schizophrenia. 2012 , 6, 31		14
405	Olanzapine discontinuation for schizophrenia. <i>The Cochrane Library</i> , 2012 ,	5.2	1
404	Positron emission tomography experience with 2- ^[18F] fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2- ^[18F] FA) in the living human brain of smokers with paranoid schizophrenia. 2012 , 66, 352-68		24
403	The genetic architecture of schizophrenia: new mutations and emerging paradigms. 2012 , 63, 63-80		82
402	Recent genomic advances in schizophrenia. 2012 , 81, 103-9		70
401	Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. 2012 , 24, 130-46		83
400	Schizophrenia as a neuronal synaptic disorder related to multiple rare genetic mutations. 2012 , 24, 39-42		
399	GABBR1 has a HERV-W LTR in its regulatory region--a possible implication for schizophrenia. 2013 , 8, 5		19
398	Aripiprazole versus other atypical antipsychotics for schizophrenia. 2013 , CD006569		14
397	Behavioural alterations relevant to developmental brain disorders in mice with neonatally induced ventral hippocampal lesions. 2013 , 94, 71-81		19
396	Association of MTHFR C677T polymorphism with schizophrenia and its effect on episodic memory and gray matter density in patients. 2013 , 243, 146-52		19
395	Polypharmacy in Psychiatry Practice, Volume I. 2013 ,		4
394	Interaction between parental psychosis and risk factors during pregnancy and birth for schizophrenia - the Northern Finland 1966 Birth Cohort study. <i>Schizophrenia Research</i> , 2013 , 145, 56-62	3.6	22

393	Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. 2013 , 22, 539-55		79
392	Mental disorders as "brain diseases" and Jaspers' legacy. 2013 , 12, 1-3		18
391	Anti-brain autoantibodies in the serum of schizophrenic patients: a case-control study. 2013 , 210, 800-5		13
390	Association between antibodies to multiple infectious and food antigens and new onset schizophrenia among US military personnel. <i>Schizophrenia Research</i> , 2013 , 151, 36-42	3.6	17
389	Renaming schizophrenia: keeping up with the facts. <i>Schizophrenia Research</i> , 2013 , 148, 1-2	3.6	19
388	Evidence of a dimensional relationship between schizotypy and schizophrenia: a systematic review. 2013 , 37, 317-27		195
387	Synthesis and evaluation of meta substituted 1-(aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics. 2013 , 22, 382-391		3
386	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. 2013 , 263, 65-74		15
385	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). 2013 , 6, 4-16		78
384	Superior mentalizing abilities of female patients with schizophrenia. 2013 , 210, 794-9		35
383	Lifetime and 12-month prevalence rates of sub-clinical psychosis symptoms in a community cohort of 50-year-old individuals. 2013 , 28, 302-7		10
382	Caregiving appraisal in schizophrenia: a study from India. 2013 , 98, 135-40		22
381	Effects of lurasidone on executive function in common marmosets. 2013 , 246, 125-31		15
380	Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. <i>Schizophrenia Research</i> , 2013 , 148, 59-66	3.6	47
379	Schizophrenia susceptibility and age of diagnosis—a frailty approach. <i>Schizophrenia Research</i> , 2013 , 147, 140-146	3.6	3
378	Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. <i>Schizophrenia Research</i> , 2013 , 148, 81-6	3.6	31
377	Drosophila strategies to study psychiatric disorders. 2013 , 92, 1-11		53
376	25 years of editing Schizophrenia research: a unique and gratifying journey. <i>Schizophrenia Research</i> , 2013 , 143, 1-2	3.6	1

375	Further evidence for the association between the LSM1 gene and schizophrenia. <i>Schizophrenia Research</i> , 2013 , 150, 588-9	3.6	7
374	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). 2013 , 6, 4-16		3
373	Motor stereotypies and cognitive perseveration in non-human primates exposed to early gestational irradiation. 2013 , 248, 213-24		14
372	Differences in associations between cannabis and stimulant disorders in first admission psychosis. <i>Schizophrenia Research</i> , 2013 , 147, 216-22	3.6	18
371	Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study. 2013 , 2013, 423205		5
370	Recent advances in quantitative neuroproteomics. 2013 , 61, 186-218		93
369	Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors. 2013 , 263, 273-84		36
368	Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological "minefield". 2013 , 354, 247-57		7
367	Developmental neuroinflammation and schizophrenia. 2013 , 42, 20-34		209
366	Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus. 2013 , 47, 872-9		8
365	Peripubertal viral-like challenge and social isolation mediate overlapping but distinct effects on behaviour and brain interferon regulatory factor 7 expression in the adult Wistar rat. 2013 , 27, 71-9		21
364	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. 2013 , 237, 86-95		22
363	C-reactive protein is elevated in schizophrenia. <i>Schizophrenia Research</i> , 2013 , 143, 198-202	3.6	87
362	Choroid plexus papilloma presenting as schizophrenia: a case report. 2013 , 25, E26-7		8
361	Structural brain alterations associated with schizophrenia preceded by conduct disorder: a common and distinct subtype of schizophrenia?. 2013 , 39, 1115-28		41
360	A Novel Approach to Predict Schizophrenia Disease: Conceptual Framework. 2013 , 284-287, 1596-1600		
359	Schizophrenia Spectrum and Other Psychotic Disorders. 2013 , 48, 33-39		3
358	Schizophrenia Spectrum and Other Psychotic Disorders. 2013 , 48, 40		

357	Early intervention and the treatment of prodrome in schizophrenia: a review of recent developments. 2013 , 19, 375-85		10
356	Secondary psychoses: an update. 2013 , 12, 4-15		96
355	Genetics of Schizophrenia. 2013 , 42, 5-22		3
354	The Psychotic Face of the Immune System: Inflammation and Schizophrenia. 2013 , 411-424		
353	Schizophrenia and OCD: comparative characteristics. 1-21		1
352	[Antipsychotic prescription patterns in patients affiliated to the Social Security Health System in Colombia]. 2013 , 33, 418-28		6
351	The neuroimmunology of schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013 , 11, 107-173.4		44
350	Alterations of white matter integrity related to the season of birth in schizophrenia: a DTI study. <i>PLoS ONE</i> , 2013 , 8, e75508	3-7	10
349	Potential Impact of miR-137 and Its Targets in Schizophrenia. 2013 , 4, 58		87
348	. 2013 ,		3
347	Correlation of Lifetime Symptom Dimensions with Cognitive Function and Other Clinical Characteristics in Schizophrenia Patients. 2014 , 17, 72		
346	The Concept of Schizophrenia: From Unity to Diversity. 2014 , 2014, 1-39		6
345	Reduced expression of nogo-a leads to motivational deficits in rats. 2014 , 8, 10		13
344	Factors related to Suicidal Ideation in People with Schizophrenia and Suicide Attempts. 2014 , 23, 259		2
343	Role of cognitive enhancement in schizophrenia. 2014 , 75		0
342	Offending behaviours of persons with schizophrenia: a case review of psychiatric halfway houses in Hong Kong. 2014 , 7, 14-25		
341	An Evolutionary Life History Framework for Psychopathology. 2014 , 25, 261-300		209
340	Aetiology of schizophrenia and implications for nursing practice: a literature review. 2014 , 35, 732-8		11

339	Antipsychotics and the Dopamine&Beronin Connection. 2014 , 1-49	1
338	Behavior Genetics of Psychopathology. 2014 ,	
337	Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients: results from electronic Schizophrenia Treatment Adherence Registry (e-STAR) and Trial for the Initiation and Maintenance Of REmission in Schizophrenia with risperidone (TIMORES). 2014 , 8, 39-49	13
336	Cognitive deconstruction of parenting in schizophrenia: the role of theory of mind. 2014 , 48, 249-58	16
335	Identification of SNP interactions using data-parallel primitives on GPUs. 2014 ,	2
334	Genetic association study between methyl-CpG-binding domain genes and schizophrenia among Chinese family trios. 2014 , 24, 221-4	2
333	Co-occurrence of psychotic experiences and common mental health conditions across four racially and ethnically diverse population samples. 2014 , 44, 3503-13	79
332	Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases. 2014 , 7, 1028-48	116
331	Gender identity disorder and schizophrenia: neurodevelopmental disorders with common causal mechanisms?. 2014 , 2014, 463757	18
330	How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library. 2014 , 44, 3387-405	18
329	Association of parental communication deviance with offspring's psychiatric and thought disorders. A systematic review and meta-analysis. 2014 , 29, 20-31	10
328	Convergent lines of evidence support CAMKK2 as a schizophrenia susceptibility gene. 2014 , 19, 774-83	36
327	What are the similarities and differences between schizophrenia and schizophrenia-like psychosis of epilepsy? A neuropathological approach to the understanding of schizophrenia spectrum and epilepsy. 2014 , 38, 143-7	7
326	The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014 , 49, 169-82	4.5 60
325	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2014 , CD006569	40
324	Schizophrenia. 2014 ,	5
323	Inflammatory cytokine network in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2014 , 15, 174-87	3.8 35
322	The Nicotine Hypothesis. 2014 , 313-332	2

321	Curious cases: Acromegaly and schizophrenia: an incidental association?. 2014 , 40, 740-3		3
320	The adenosine neuromodulation system in schizophrenia. 2014 , 119, 395-449		27
319	Dysbindin-associated proteome in the p2 synaptosome fraction of mouse brain. 2014 , 13, 4567-80		11
318	Developing tomorrow's antipsychotics: the need for a more personalised approach. 2014 , 20, 3-12		3
317	Insights from Proteomic Studies on Schizophrenia Preclinical Models: What Can We Learn for Drug Discovery?. 2014 , 56-56		1
316	Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models. 2014 , 211, 79-112		17
315	Schizophrenia: Blood-Serum-Plasma Metabolomics. 2014 , 27-27		
314	Sex differences in first-episode psychosis and in people at ultra-high risk. 2014 , 215, 314-22		19
313	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. <i>Schizophrenia Research</i> , 2014 , 156, 107-14	3.6	16
312	Association of decreased prefrontal hemodynamic response during a verbal fluency task with EGR3 gene polymorphism in patients with schizophrenia and in healthy individuals. 2014 , 85 Pt 1, 527-34		20
311	Demographic features and premorbid personality disorder traits in relation to age of onset and sex in paranoid schizophrenia. 2014 , 215, 554-9		11
310	Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia. 2014 , 24, 774-87		15
309	The economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matching. 2014 , 29, 479-89		36
308	Clozapine directly increases insulin and glucagon secretion from islets: implications for impairment of glucose tolerance. <i>Schizophrenia Research</i> , 2014 , 157, 128-33	3.6	15
307	Pharmacogenetics of antipsychotics. 2014 , 59, 76-88		62
306	Association between single nucleotide polymorphisms in MiR219-1 and MiR137 and susceptibility to schizophrenia in a Chinese population. 2015 , 5, 774-8		12
305	Predictors of the Onset of Schizophrenia in US Military Personnel. 2015 , 203, 319-24		3
304	Detection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools. 2015 , 13, 432-440		2

303	CACNA1C gene and schizophrenia: a case-control and pharmacogenetic study. 2015 , 25, 163-7		19
302	Metacognition in Early Phase Psychosis: Toward Understanding Neural Substrates. 2015 , 16, 14640-54		10
301	Jumping to conclusions style along the continuum of delusions: delusion-prone individuals are not hastier in decision making than healthy individuals. <i>PLoS ONE</i> , 2015 , 10, e0121347	3.7	9
300	Comparative Study on Serum Levels of 10 Trace Elements in Schizophrenia. <i>PLoS ONE</i> , 2015 , 10, e0133627	3.7	23
299	Association between Unmet Needs and Clinical Status in Patients with First Episode of Schizophrenia in Chile. <i>Frontiers in Psychiatry</i> , 2015 , 6, 57	5	6
298	The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. 2015 , 300, 141-54		376
297	Maternal lipopolysaccharide treatment differentially affects 5-HT(2A) and mGlu2/3 receptor function in the adult male and female rat offspring. 2015 , 97, 275-88		27
296	Methylation of a HTR3A promoter variant alters the binding of transcription factor CTCF. 2015 , 5, 45710-45717		5
295	Social-Cognitive Deficits in Schizophrenia. 2017 , 30, 397-409		29
294	Dficit en el procesamiento auditivo subcortical en pacientes esquizofrnicos. Revisi3n sobre posibles biomarcadores neurofisiol3gicos. 2015 , 22, 67-70		67
293	Schizophrenia Patient or Spiritually Advanced Personality? A Qualitative Case Analysis. 2015 , 54, 1901-18		6
292	Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. 2015 , 29, 116-26		36
291	Reelin influences the expression and function of dopamine D2 and serotonin 5-HT2A receptors: a comparative study. 2015 , 290, 165-74		11
290	Small Molecule Therapeutics for Schizophrenia. 2015 ,		1
289	Abnormal white matter integrity in antipsychotic-naïve first-episode psychosis patients assessed by a DTI principal component analysis. <i>Schizophrenia Research</i> , 2015 , 162, 14-21	3.6	25
288	Evidence for schizophrenia susceptibility alleles in the Indian population: An association of neurodevelopmental genes in case-control and familial samples. <i>Schizophrenia Research</i> , 2015 , 162, 112-7	3.6	21
287	Much ado about much: stress, dynamic biomarkers and HPA axis dysregulation along the trajectory to psychosis. <i>Schizophrenia Research</i> , 2015 , 162, 253-60	3.6	48
286	Asperger syndrome and schizophrenia: Overlap of self-reported autistic traits using the Autism-spectrum Quotient (AQ). 2015 , 69, 268-74		30

285	Adapting supported employment for emerging adults with serious mental health conditions. 2015 , 42, 206-22		36
284	Molecular modeling and docking study on dopamine D2-like and serotonin 5-HT2A receptors. 2015 , 57, 143-55		16
283	Association of chromosome 5q21.3 polymorphisms with the exploratory eye movement dysfunction in schizophrenia. 2015 , 5, 10299		4
282	Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load. 2015 , 60, 120-9		38
281	The influence of AHI1 variants on the diagnosis and treatment outcome in schizophrenia. 2015 , 16, 2517-29		11
280	Association of adoptive child's thought disorders and schizophrenia spectrum disorders with their genetic liability for schizophrenia spectrum disorders, season of birth and parental Communication Deviance. 2015 , 226, 434-40		6
279	Constant light uncovers behavioral effects of a mutation in the schizophrenia risk gene Dtnbp1 in mice. 2015 , 284, 58-68		17
278	The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties. 2015 , 86, 435-47		9
277	Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions. 2015 , 27, 615-35		41
276	Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands--A review. 2015 , 70, 50-7		64
275	Low expression of Gria1 and Grin1 glutamate receptors in the nucleus accumbens of Spontaneously Hypertensive Rats (SHR). 2015 , 229, 690-4		7
274	Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. <i>Schizophrenia Research</i> , 2015 , 169, 234-240	3.6	26
273	New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent findings. 2015 , 58, 704-14		27
272	Differences in the burden of psychiatric comorbidity in MS vs the general population. 2015 , 85, 1972-9		81
271	Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia. 2014 , 18,		18
270	Nodal centrality of functional network in the differentiation of schizophrenia. <i>Schizophrenia Research</i> , 2015 , 168, 345-52	3.6	43
269	Psychiatry is a clinical neuroscience, but how do we move the field?. <i>Asian Journal of Psychiatry</i> , 2015 , 17, 135-7	6.7	9
268	Dermatoglyphic correlates of hippocampus volume: Evaluation of aberrant neurodevelopmental markers in antipsychotic-naïve schizophrenia. 2015 , 234, 113-20		4

267	Assessing sub-clinical psychosis phenotypes in the general population--a multidimensional approach. <i>Schizophrenia Research</i> , 2015 , 161, 194-201	3.6	25
266	Dendritic spine alterations in schizophrenia. 2015 , 601, 46-53		80
265	Decrease in olfactory and taste receptor expression in the dorsolateral prefrontal cortex in chronic schizophrenia. 2015 , 60, 109-16		39
264	Neurodevelopment, GABA system dysfunction, and schizophrenia. 2015 , 40, 190-206		127
263	Prenatal LPS-exposure--a neurodevelopmental rat model of schizophrenia--differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring. 2015 , 57, 17-30		103
262	A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. 2015 , 14, 411-21		24
261	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequencesâpart 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. 2015 , 265, 87-106		19
260	Neuroinflammation and white matter pathology in schizophrenia: systematic review. <i>Schizophrenia Research</i> , 2015 , 161, 102-12	3.6	190
259	Le d'voilement de soi chez les hommes vivant avec la schizophr'nie. 2016 , N° 126, 80		1
258	Symptoms and Etiological Attribution: A Cross-Sectional Study in Mexican Outpatients with Psychosis and Their Relatives. 2016 , 2016, 9549683		
257	Immigration and Risk of Psychiatric Disorders: A Review of Existing Literature. 2016 , 11, 3-5		11
256	Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip. <i>PLoS ONE</i> , 2016 , 11, e0150464	3.7	10
255	Establishing the "Fit" between the Patient and the Therapy: The Role of Patient Gender in Selecting Psychological Therapy for Distressing Voices. 2016 , 7, 424		5
254	Inferring the Dysconnection Syndrome in Schizophrenia: Interpretational Considerations on Methods for the Network Analyses of fMRI Data. <i>Frontiers in Psychiatry</i> , 2016 , 7, 132	5	25
253	Cognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial Perspective. <i>Frontiers in Psychiatry</i> , 2016 , 7, 160	5	24
252	Aripiprazole versus perphenazine for people with schizophrenia and schizophrenia-like psychoses. <i>The Cochrane Library</i> , 2016 ,	5.2	
251	Aripiprazole versus sulpiride for people with schizophrenia and schizophrenia-like psychoses. <i>The Cochrane Library</i> , 2016 ,	5.2	
250	Genetic association between NRG1 and schizophrenia, major depressive disorder, bipolar disorder in Han Chinese population. 2016 , 171B, 468-78		18

249	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. 2016 , 9, 219-227		3
248	Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia-like psychoses. <i>The Cochrane Library</i> , 2016 ,	5.2	3
247	Aripiprazole versus chlorpromazine for people with schizophrenia and schizophrenia-like psychoses. <i>The Cochrane Library</i> , 2016 ,	5.2	1
246	Bridging the schism of schizophrenia through yoga-Review of putative mechanisms. 2016 , 28, 254-64		17
245	Genetic Variation in Schizophrenia Liability is Shared With Intellectual Ability and Brain Structure. 2016 , 42, 1167-75		17
244	PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study. 2016 , 73, 160-8		8
243	Stress Sensitivity and Psychotic Experiences in 39 Low- and Middle-Income Countries. 2016 , 42, 1353-1362		41
242	The ACIPS: Moving forward in the assessment of negative symptoms. <i>Schizophrenia Research</i> , 2016 , 176, 327-328	3.6	4
241	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. 2016 , 9, 219-227		16
240	Signing off as Editor-in-Chief. <i>Schizophrenia Research</i> , 2016 , 175, 2-3	3.6	
239	Toxoplasma gondii infection in schizophrenia and associated clinical features. 2016 , 245, 327-332		22
238	miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia. 2016 , 245, 200-206		31
237	Does Schizophrenia in Offspring Increase the Risk of Developing Alzheimer's Dementia. 2016 , 6, 361-373		5
236	The mental health and wellbeing of first generation migrants: a systematic-narrative review of reviews. 2016 , 12, 47		93
235	Stratifying empiric risk of schizophrenia among first degree relatives using multiple predictors in two independent Indian samples. <i>Asian Journal of Psychiatry</i> , 2016 , 24, 79-84	6.7	4
234	Genetics and Family Systems: Articulation and Disarticulation. 2016 , 1-39		
233	Resilience in Patients With Recent Diagnosis of a Schizophrenia Spectrum Disorder. 2016 , 204, 578-84		16
232	Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. 2016 , 21, 1009-26		197

231	Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology. <i>Schizophrenia Research</i> , 2016 , 177, 98-107	3.6	8
230	Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. 2016 , 110, 49-58		12
229	Neuropsychological correlates of remission in chronic schizophrenia subjects: The role of general and task-specific executive processes. 2016 , 3, 39-46		4
228	Similar white matter but opposite grey matter changes in schizophrenia and high-functioning autism. 2016 , 134, 31-9		26
227	Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. 2016 , 25, 38-48		16
226	Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. <i>Schizophrenia Research</i> , 2016 , 171, 166-75	3.6	22
225	Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI. 2016 , 7, 312-7		7
224	Preventing Schizophrenia and Severe Mental Illness: A Grand Challenge for Social Work. <i>Research on Social Work Practice</i> , 2016 , 26, 449-459	1.4	8
223	Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring. 2016 , 299, 72-80		23
222	Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016 , 51, 475-91	4.5	39
221	I Believe I Can Fly!: Use of Drosophila as a Model Organism in Neuropsychopharmacology Research. 2016 , 41, 1439-46		18
220	Animal models of gene-environment interaction in schizophrenia: A dimensional perspective. 2016 , 136, 1-27		54
219	Pathophysiological Role of HERV-W in Schizophrenia. 2016 , 28, 17-25		7
218	Association study between the neurexin-1 gene and tardive dyskinesia. 2017 , 32, e2568		6
217	Blonanserin versus risperidone for schizophrenia. <i>The Cochrane Library</i> , 2017 ,	5.2	78
216	Youth mental ill health and secondary school completion in Australia: time to act. 2017 , 11, 277-289		18
215	Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. 2017 , 34, 1482-1497		3
214	Relations among adults' remembrances of parental acceptance-rejection in childhood, self-reported psychological adjustment, and adult psychopathology. 2017 , 77, 27-37		5

213	Schizophrenia and Psychosis: Diagnosis, Current Research Trends, and Model Treatment Approaches with Implications for Transitional Age Youth. 2017 , 26, 341-366		27
212	Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. 2017 , 26, 424-429		32
211	Research in Clinical Pragmatics. 2017 ,		15
210	Psychiatric Care in Severe Obesity. 2017 ,		1
209	Phytochemicals Effects on Neurodegenerative Diseases. 2017 , 85-114		
208	Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice. 2017 , 31, 1511-1518		29
207	Attachment and thought problems in an adolescent inpatient sample: The mediational role of theory of mind. 2017 , 78, 38-47		7
206	Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. 2017 , 20, 1039-1047		15
205	Novel gene-brain structure relationships in psychotic disorder revealed using parallel independent component analyses. <i>Schizophrenia Research</i> , 2017 , 182, 74-83	3.6	9
204	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. 2017 , 81, 470-477		126
203	PDE7B, NMBR and EPM2A variants and schizophrenia: a case-control and pharmacogenetics study. 2017 , 27, S577-S578		
202	A Case-Control Study of the Association between Polymorphisms in the Fibrinogen Alpha Chain Gene and Schizophrenia. 2017 , 2017, 3104180		4
201	Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-one (TAK-915), for the Treatment of Cognitive Disorders. 2017 , 65, 1058-1077		9
200	The Subjective-Objective Disjunction in Psychometrically-Defined Schizotypy: What it is and Why it is Important?. 2017 , 8, 347-363		9
199	Reducing Neuroinflammation in Psychiatric Disorders: Novel Target of Phosphodiesterase 4 (PDE4) and Developing of the PDE4 Inhibitors. 2017 ,		
198	Bayesian Analyses of the Effect of Metacognitive Training on Social Cognition Deficits and Overconfidence in Errors. 2017 , 8, 158-174		12
197	Neuroinflammation and Neurotransmission Mechanisms Involved in Neuropsychiatric Disorders. 2017 ,		2
196	N-Acetylcystein: neue Option zur frühen Bekämpfung von Schizophrenie. 2018 , 19, 28-34		

195	High neutrophil-lymphocyte ratio in schizophrenia independent of infectious and metabolic parameters. 2018 , 72, 336-340		22
194	Gray and white matter changes and their relation to illness trajectory in first episode psychosis. 2018 , 28, 392-400		11
193	Hot Genes in Schizophrenia: How Clinical Datasets Could Help to Refine their Role. 2018 , 64, 273-286		4
192	Dysregulation of miRNA and its potential therapeutic application in schizophrenia. 2018 , 24, 586-597		22
191	[Depression in relatives of patients with schizophrenia: 8-month longitudinal outcome of ProFamille Program]. 2018 , 44, 128-133		3
190	The interaction between subclinical psychotic experiences, insomnia and objective measures of sleep. <i>Schizophrenia Research</i> , 2018 , 193, 204-208	3.6	16
189	Interaction between compound genetic risk for schizophrenia and high birth weight contributes to social anhedonia and schizophrenia in women. 2018 , 259, 148-153		9
188	A-582941, cholinergic alpha 7 nicotinic receptor agonist, improved cognitive and negative symptoms of the sub-chronic MK-801 model of schizophrenia in rats. 2018 , 28, 4-13		3
187	N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. 2018 , 44, 317-327		83
186	Negative symptoms of psychosis: A life course approach and implications for prevention and treatment. 2018 , 12, 561-571		18
185	A systematic review of the structural neuroimaging correlates of thought disorder. 2018 , 84, 299-315		28
184	Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. 2018 , 177, 3-9		3
183	Patrones de prescripci3n de psicofarmacos en pacientes con esquizofrenia y trastornos relacionados internados en el Hospital V3ctor Larco Herrera, 2015. 2018 , 78, 386		0
182	microRNAs Sculpt Neuronal Communication in a Tight Balance That Is Lost in Neurological Disease. 2018 , 11, 455		24
181	Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia. 2018 , 270, 357-364		8
180	Migration and Psychosis. 2018 , 1-25		
179	Prevalence and pattern of mental illnesses in Uttar Pradesh, India: Findings from the National Mental Health Survey 2015-16. <i>Asian Journal of Psychiatry</i> , 2018 , 38, 45-52	6.7	11
178	First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. 2018 , 18, 274		8

177	cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia. 2018 , 11, 255		108
176	Comparative study of aggression - Dangerousness on patients with paranoid schizophrenia: Focus on demographic data, PANSS, drug use and aggressiveness. 2018 , 60, 1-11		9
175	Mental disorders and an acidic glycan-from the perspective of polysialic acid (PSA/polySia) and the synthesizing enzyme, ST8SIA2. 2018 , 35, 353-373		8
174	Childhood-Onset Schizophrenia. 2018 , 211-223		
173	Value of schizophrenia treatment I: The patient journey. 2018 , 53, 107-115		17
172	The experiences of providing caregiving for patients with schizophrenia in the Ghanaian context. 2018 , 32, 815-822		42
171	Surprising conservation of schizophrenia risk genes in lower organisms reflects their essential function and the evolution of genetic liability. <i>Schizophrenia Research</i> , 2018 , 202, 120-128	3.6	9
170	Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampi of Chronic Restraint Stress Rats. 2018 , 2018, 2682037		10
169	Investigational and Therapeutic Applications of Transcranial Magnetic Stimulation in Schizophrenia. 2019 , 21, 89		15
168	Acute stress-induced change in polysialic acid levels mediated by sialidase in mouse brain. 2019 , 9, 9950		12
167	B-cells and schizophrenia: A promising link or a finding lost in translation?. 2019 , 81, 52-62		5
166	12-Month stability of neurological soft signs in stabilized patients with schizophrenia. 2019 , 73, 451-461		2
165	Breakthrough psychosis under antipsychotic maintenance treatment and social stress. 2019 , 49, 2808-2809		
164	The Bed Nucleus of the Stria Terminalis, Homeostatic Satiety, and Compulsions: What Can We Learn From Polydipsia?. 2019 , 13, 170		3
163	Serum PGE2, 15d-PGJ, PPAR α and CRP levels in patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2019 , 46, 24-28	6.7	6
162	Hair cortisol concentrations as an indicator of potential HPA axis hyperactivation in risk for psychosis. <i>Schizophrenia Research</i> , 2019 , 212, 54-61	3.6	3
161	Dentate Gyrus Immaturity in Schizophrenia. 2019 , 25, 528-547		9
160	Altered Cellular White Matter But Not Extracellular Free Water on Diffusion MRI in Individuals at Clinical High Risk for Psychosis. 2019 , 176, 820-828		14

159	Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies. 2019 , 108, 3082-3090		35
158	Meta-analysis of genomic variants and gene expression data in schizophrenia suggests the potential need for adjunctive therapeutic interventions for neuropsychiatric disorders. 2019 , 98, 1		2
157	Negative symptoms and recollections of parental rejection: The moderating roles of psychological maladjustment and gender. 2019 , 275, 332-337		2
156	Perception regarding the causes of schizophrenia and associated factors among Feresbet district residents: a community based study. 2019 , 19, 338		3
155	Quetiapine dose for people with schizophrenia. <i>The Cochrane Library</i> , 2019 ,	5.2	0
154	Borderline Personality Pathology in an At Risk Mental State Sample. <i>Frontiers in Psychiatry</i> , 2019 , 10, 838	5	4
153	Altered Expression of a Unique Set of Genes Reveals Complex Etiology of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019 , 10, 906	5	2
152	Rs7219 Regulates the Expression of GRB2 by Affecting miR-1288-Mediated Inhibition and Contributes to the Risk of Schizophrenia in the Chinese Han Population. 2019 , 39, 137-147		2
151	Early childhood social communication deficits in youth at clinical high-risk for psychosis: Associations with functioning and risk. 2020 , 32, 559-572		6
150	Glial cells in schizophrenia: a unified hypothesis. 2020 , 7, 272-281		61
149	Childhood-Onset Schizophrenia and Early-onset Schizophrenia Spectrum Disorders: An Update. 2020 , 29, 71-90		31
148	Association of physical health multimorbidity with mortality in people with schizophrenia spectrum disorders: Using a novel semantic search system that captures physical diseases in electronic patient records. <i>Schizophrenia Research</i> , 2020 , 216, 408-415	3.6	14
147	Voice patterns in schizophrenia: A systematic review and Bayesian meta-analysis. <i>Schizophrenia Research</i> , 2020 , 216, 24-40	3.6	24
146	The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. 2020 , 19, 43-57		19
145	Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. <i>Schizophrenia Research</i> , 2020 , 223, 59-70	3.6	12
144	Subtyping schizophrenia based on symptomatology and cognition using a data driven approach. 2020 , 304, 111136		1
143	Positive association between PTN polymorphisms and schizophrenia in Northeast Chinese Han population. 2020 , 30, 141-149		1
142	Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders. 2020 , 6, e03990		4

141	An evolutionary life history approach to understanding mental health. 2020 , 33, e100113		2
140	Schizophrenia: Developmental Variability Interacts with Risk Factors to Cause the Disorder: Nonspecific Variability-Enhancing Factors Combine with Specific Risk Factors to Cause Schizophrenia. 2020 , 42, e2000038		1
139	Voluntary and Forced Migrants in Forensic Mental Health Care. 2020 , 19, 391-402		2
138	Galectin-1 and Galectin-3 Levels in Patients with Schizophrenia and their Unaffected Siblings. 2020 , 91, 715-725		2
137	Increasing diversity within scientific research organizations: A call to action. <i>Schizophrenia Research</i> , 2020 , 216, 7-9	3.6	3
136	Magical thinking as a bio-psychological developmental disposition for cognitive and affective symptoms intensity in schizotypy: Traits and genetic associations. 2021 , 171, 110498		0
135	No mental health research without qualitative research. 2021 , 8, 266-267		3
134	Different positron emission tomography findings in schizophrenia and narcolepsy type 1 in adolescents and young adults: a preliminary study. 2021 , 17, 739-748		0
133	Polysialylation and disease. 2021 , 79, 100892		14
132	Obsessive-Compulsive Schizophrenia and Obsessive-Compulsive Disorder. 2021 , 33-52		
131	Migration and Psychosis. 2021 , 321-345		
130	A Nationwide Cohort Study of Nonrandom Mating in Schizophrenia and Bipolar Disorder. 2021 , 47, 1342-1350	3	
129	Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases. 2021 , 143, 487-494		0
128	Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review. 2021 , 11,		2
127	Transcriptional regulation of schizophrenia risk gene TCF4 in inhibitory neurons during neurodevelopment.		
126	Advances in Proteomics Allow Insights Into Neuronal Proteomes. 2021 , 14, 647451		0
125	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia. 2021 , 17, 1289-1297		0
124	Birth Seasonality of Schizophrenia and Bipolar Disorder? A Review of Inpatient Records. 2021 , 287, 15-18		2

123	One Pot Synthesis and Pharmacological Evaluation of Aryl Substituted Imidazoles as Potential Atypical Antipsychotics. 2021 , 18, 338-354		
122	Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics. 2021 , 13,		0
121	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. 2021 ,		2
120	Application of animal experimental models in the research of schizophrenia. 2021 , 186, 209-227		2
119	Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. 2021 , 9, 24932		1
118	Treatment patterns and appropriateness of antipsychotic prescriptions in patients with schizophrenia. 2021 , 11, 13509		1
117	Levels of lymphocyte-associated regulators of complement system CD55 and CD59 are changed in schizophrenia patients. 2021 , 25, 277-282		1
116	Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. 2021 , 11, 277-296		4
115	In-situ genomic prediction using low-coverage Nanopore sequencing.		
114	Accelerated aging signatures in subjects with schizophrenia and their unaffected siblings. 2021 , 139, 30-37		0
113	Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. 2021 ,		2
112	[Metacognitive deficit in schizophrenia: Characteristics and links]. 2021 ,		
111	Resting-state functional connectivity predictors of treatment response in schizophrenia - A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2021 , 237, 153-165	3.6	1
110	Role of Polysialic Acid in Schizophrenia. 2021 , 276-286		
109	Paranoid Schizophrenia With Voices and Panic Anxiety. 2021 , 53-65		
108	Parenting skills of patients with chronic schizophrenia. 2021 , 63, 58-65		
107	Behavioural Interventions for Weight Management Among Patients with Schizophrenia. 2017 , 257-273		1
106	Schizophrenia. 2017 , 267-290		7

105	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. 2017 , 147-191		2
104	Depression and Psychosis in Neurological Practice. 2012 , 92-116		5
103	Persistence criteria for susceptibility genes for schizophrenia: a discussion from an evolutionary viewpoint. <i>PLoS ONE</i> , 2009 , 4, e7799	3-7	21
102	Network-Based Analysis of Schizophrenia Genome-Wide Association Data to Detect the Joint Functional Association Signals. <i>PLoS ONE</i> , 2015 , 10, e0133404	3-7	24
101	Model-based optimization approaches for precision medicine: A case study in presynaptic dopamine overactivity. <i>PLoS ONE</i> , 2017 , 12, e0179575	3-7	3
100	Causas "fracas" e redes causais complexas em psiquiatria. 2014 , 17, 15-28		1
99	Future directions in the treatment of schizophrenia. 2012 , 66-79		1
98	Unemployment as a Risk Factor for Mental Illness: Combining Social and Psychiatric Literature. 2013 , 03, 131-136		6
97	Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 1-12	3-4	7
96	A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012 , 10, 61-70	3-4	60
95	Model-driven Assessment of the Effects of Brain-derived Neurotrophic Factor Deficiency on Glutamate and Gamma-Aminobutyric Acid: Implications for Understanding Schizophrenia Pathophysiology. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017 , 15, 115-125	3-4	5
94	Verification of the Availability of Individual Proteins for Quantitative Analysis in Brains Preserved in Two Different Brain Banks Using GAPDH and GFAP.		
93	MicroRNAs in the Onset of Schizophrenia. 2021 , 10,		3
92	Genetic counseling in schizophrenia. 2009 , 322-332		
91	Mutant and Transgenic Tools in Modeling Schizophrenia. 2010 , 217-239		
90	Gemeinsame Risikogene von affektiven und schizophrenen Erkrankungen. 2010 , 93-103		
89	References. 2010 , 335-393		
88	Genetics in schizophrenia: where are we and what next?. 2010 , 12, 289-303		28

87 The Relationship Between Nutrition and Neurocognitive Function in Schizophrenia. **2011**, 1859-1872

86 Genetik bei psychischen Erkrankungen. **2011**, 127-165

85 Coronary Heart Disease, Diet and Neurocognitive Functioning. **2011**, 1555-1566

84 Formas deficitária e não deficitária da esquizofrenia não diferem quanto à sazonalidade de nascimentos nas regiões Sul e Sudeste do Brasil. **2011**, 60, 337-340

83 Psychiatrische Erkrankungen. **2012**, 467-479

82 Bibliographie. **2012**, 151-167

81 Psychotic Disorders. 418-434

80 Glutamatergic Synaptic Dysregulation in Schizophrenia. 115-142

79 Antidepressants in Schizophrenia: A Place for Them?. **2013**, 211-231

78 Soft psychological and sociological factors in a hard psychiatric disorder: The mystery of schizophrenia. **2013**, 68, 127-140 1

77 Mental Illness from an Asian American Perspective. **2014**, 77-90

76 Melatonin in the Etiology, Pathophysiology, and Management of Schizophrenia. **2014**, 307-320

75 Introduction. **2014**, 3-12

74 Schizophrenia and Bipolar Disorder. **2014**, 153-183

73 Encyclopedia of Psychopharmacology. **2014**, 1-8

72 Latest findings in the genetic architecture of schizophrenia: The contribution of genetic studies among Afrikaners. *South African Journal of Science and Technology*, **2014**, 33, 0.1

71 Early Antipsychotic Response Predictors in Schizophrenia: A Naturalistic Study. *Journal of Psychology & Clinical Psychiatry*, **2014**, 1, 1

70 Schizophrenia. **2015**, 361-380

- 69 CHAPTER 3:Developmental Neuroimmune Mechanisms in Schizophrenia. *RSC Drug Discovery Series*, **2015**, 46-69 0.6
- 68 Schizophrenien und andere psychotische Störungen. **2015**, 349-412
- 67 Long-Term Clinical Outcome of Patients Using Risperidone Long-Acting Injectable: The Romanian e-STAR Database. *Open Journal of Psychiatry*, **2015**, 05, 153-164 0.2
- 66 References. **2015**, 165-183
- 65 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2016**, 1-45
- 64 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2017**, 1-45
- 63 Altered expression of a unique set of genes reveals complex etiology of Schizophrenia.
- 62 Evidenzbasierte Interventionen in der frühen Entwicklungsphase schizophrener Störungen. *Zeitschrift Fur Psychiatrie, Psychologie Und Psychotherapie*, **2017**, 65, 113-120 0.3 1
- 61 Second-Generation Antipsychotics Clinical Pharmacy Plan Developed from Hospital Pharmacy to Primary Health Care. *Pharmacy & Pharmacology International Journal*, **2017**, 5, 0.7
- 60 Encyclopedia of Adolescence. **2018**, 3236-3238
- 59 Psychosen. **2018**, 133-164
- 58 Multi-scale analysis of schizophrenia risk loci: Integrating centenarian genomes and spatio-temporal expression profiles suggests the need for adjunctive therapeutic interventions for neuropsychiatric disorders. 0
- 57 Schizophrenien und andere psychotische Störungen. **2019**, 301-362.e7
- 56 Épisodes psychotiques aigus à l'âge précoce dans les troubles du spectre de la schizophrénie. **2019**, 381-385
- 55 Comment comprendre l'apparition des psychoses?. **2019**, 3-16
- 54 Mothers of schizophrenic patients: medical and psychological aspects of the problem. *Medical Herald of the South of Russia*, **2019**, 10, 6-17 0.2 0
- 53 Toxoplasmosis: A Link To Mental Illness. *Global Journal of Zoology*, **2020**, 025-030 0.3
- 52 Chapitre 21. Les symptômes. **2020**, 411-562

51	Neuropsychological dysfunctions among chronic schizophrenia patients, alcohol dependence cases, and normal subjects: A comparative study. <i>Industrial Psychiatry</i> , 2020 , 29, 105-122	0.9	1
50	Toward earlier identification and preventative intervention in schizophrenia: evidence from the London Child Health and Development Study. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2016 , 51, 475	4.5	
49	Positive Association of Human SHC3 Gene with Schizophrenia in a Northeast Chinese Han Population. <i>Psychiatry Investigation</i> , 2020 , 17, 934-940	3.1	1
48	Narcolepsy presenting as schizophrenia: a literature review and two case reports. <i>Innovations in Clinical Neuroscience</i> , 2011 , 8, 30-4	1	16
47	Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report. <i>Iranian Journal of Psychiatry</i> , 2011 , 6, 161-3	1.9	6
46	Using focus groups to design a psychoeducation program for patients with schizophrenia and their family members. <i>International Journal of Clinical and Experimental Medicine</i> , 2014 , 7, 177-85		3
45	Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. <i>Diagnostics</i> , 2021 , 11,	3.8	2
44	Changes in the DSM Diagnostic Concept of Schizophrenia: From 1980 to 2013. <i>Journal of Korean Neuropsychiatric Association</i> , 2021 , 60, 241	0.4	
43	A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.. <i>Clinical Microbiology Reviews</i> , 2022 , e0033820	34	12
42	Network Analysis-Based Disentanglement of the Symptom Heterogeneity in Asian Patients with Schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	0
41	Primeiro episódio psicótico: atendimento de emergência. <i>Revista Debates Em Psiquiatria</i> , 2014 , 4, 16-22	0	
40	Chapitre 1. Schizophr�nie(s) : cliniques. 2015 , 5-18		
39	Severe mental disorders and vaccinations - a systematic review.. <i>World Journal of Biological Psychiatry</i> , 2022 , 1-16	3.8	0
38	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.. <i>Asian Journal of Psychiatry</i> , 2022 , 69, 103007	6.7	1
37	Explaining the Association Between Urbanicity and Psychotic-Like Experiences in Pre-Adolescence: The Indirect Effect of Urban Exposures.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 831089	5	
36	Voice patterns as markers of schizophrenia: building a cumulative generalizable approach via cross-linguistic and meta-analysis based investigation.		0
35	Genomic prediction using low-coverage portable Nanopore sequencing.. <i>PLoS ONE</i> , 2021 , 16, e0261274	3.7	0
34	Social Work Training Intervention to Increase Referral Rates for Preventive Psychosis Services: A Randomized Trial. <i>Research on Social Work Practice</i> , 2022 , 32, 322-327	1.4	

33	A Case for Thalamic Mechanisms of Schizophrenia: Perspective From Modeling 22q11.2 Deletion Syndrome.. <i>Frontiers in Neural Circuits</i> , 2021 , 15, 769969	3.5	1
32	Transformer les pratiques entre la psychiatrie de lâenfant et de lâadolescent et la psychiatrie de lâadulte pour une r�lle prvention. <i>Neuropsychiatrie De LEnfance Et De LAdolescence</i> , 2021 , 69, 401-409	0.3	
31	Table_1.docx. 2019 ,		
30	Image_1.tif. 2019 ,		
29	Table_1.docx. 2019 ,		
28	Table_2.docx. 2019 ,		
27	Pre- and Perinatal Risk Factors for Serious Mental Disorders: Ethical Considerations in Prevention and Prediction Efforts.. 2018 , 10,		
26	Feature and decision-level fusion for schizophrenia detection based on resting-state fMRI data. <i>PLoS ONE</i> , 2022 , 17, e0265300	3.7	2
25	Emerging evidence for astrocyte dysfunction in schizophrenia. <i>Glia</i> ,	9	1
24	Influence of Menstrual Cycle Length and Age at Menarche on Symptoms, Cognition, Social Cognition, and Metacognition in Patients with First-Episode Psychosis. <i>Women</i> , 2022 , 2, 135-146		0
23	Childhood maltreatment mediates the effect of the genetic background on psychosis risk in young adults. <i>Translational Psychiatry</i> , 2022 , 12,	8.6	0
22	How Variation in Risk Allele Output and Gene Interactions Shape the Genetic Architecture of Schizophrenia. <i>Genes</i> , 2022 , 13, 1040	4.2	
21	Indoleamine 2,3-dioxygenase (IDO)-activity in severe psychiatric disorders: A systemic review.. <i>Current Topics in Medicinal Chemistry</i> , 2022 , 22,	3	2
20	Bibliographie. 2012 , 99-125		
19	Cognitive behavioural therapy (group) for schizophrenia. <i>The Cochrane Library</i> , 2022 , 2022,	5.2	1
18	Machine-Learning for Prescription Patterns: Random Forest in the Prediction of Dose and Number of Antipsychotics Prescribed to People with Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022 , 20, 450-461	3.4	0
17	Biological hypotheses, risk factors, and biomarkers of schizophrenia. 2023 , 120, 110626		0
16	Modulating Specific Pathways In Vitro to Understand the Synaptic Dysfunction of Schizophrenia. 2022 , 121-127		0

- 15 Cognitive Enhancement Therapy vs social skills training in schizophrenia: a cluster randomized comparative effectiveness evaluation. **2022**, 22, ○
- 14 The alternations of nucleus accumbent in schizophrenia patients with auditory verbal hallucinations during low-frequency rTMS treatment. 13, ○
- 13 Linguistic anomalies in the language of patients with schizophrenia. **2023**, 31, 100273 ○
- 12 Effects of *Toxoplasma gondii* infection on cognition, symptoms, and response to digital cognitive training in schizophrenia. **2022**, 8, ○
- 11 A novel ternary pattern-based automatic psychiatric disorders classification using ECG signals. 6 ○
- 10 Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - Data from a Danish quality assessment audit. 1-10 ○
- 9 Decreased serum levels of ßynuclein in patients with schizophrenia and their unaffected siblings. ○
- 8 Attitudes towards schizophrenia and associated factors among community members in Hossana town: a mixed method study. **2023**, 23, ○
- 7 The Role of microRNA in the Pathogenesis of Schizophrenia. **2022**, 11, 119-132 ○
- 6 Affective lability in parents with schizophrenia or bipolar disorder and their co-parents - The Danish High Risk and Resilience Study VIA 7. **2023**, 321, 115092 ○
- 5 âReinventing schizophrenia: Updating the constructâProject update and next steps. **2023**, 252, 345-347 ○
- 4 Factors Contributing to Risk of Persistence of Positive and Negative Symptoms in Schizophrenia during Hospitalization. **2023**, 20, 4592 ○
- 3 Schizophrenia. **2022**, ○
- 2 Meta-cognitive training for schizophrenia. **2023**, 2023, ○
- 1 Mass Spectrometry based identification of site-specific proteomic alterations and potential pathways underlying the pathophysiology of schizophrenia. ○